Boston Biomedica WKN 904312 - 500 Beiträge pro Seite

[zupf]

Wer kennt diese Aktie ?
Was macht diese Unternehmen ?
Wo gibt es Infos zu diesem Unternehmen ?
Für eure hilfe wäre ich sehr dankbar !

Im vorraus vielen dank.

[bankatoer0177]

Vor ca. 2 Jahren hatte ich diese Aktie mal. Aber näheres weis ich auch nicht. Damals hatte ich sie für ca. 16 gekauft und bei 12 wieder verkauft. Ich weis nicht wie der Kurs jetzt ist. Aber die Umsätze waren schon immer sehr schwach.

[zupf]

Warum kaufst du eine Aktie ohne über das Unternehmen etwas
zu wissen ? Der aktuelle Kurs ist 2 der handel sehr gering.

[Spiewi]

http://www.bbii.com/" target="_blank" rel="nofollow ugc noopener">http://www.bbii.com/

Boston Biomedica, Inc. provides products and services for the detection and treatment of infectious diseases such as AIDS, Lyme Disease, and Viral Hepatitis. BBI has four operating business units: (1) BBI Diagnostics, an ISO 9001 certified manufacturer and supplier of quality control and diagnostics reagents used to increase the accuracy of in vitro diagnostic tests, (2) BBI Clinical Laboratories, a leading specialty infectious diseases testing laboratory, (3) BBI Biotech Research Laboratories, a research and development center providing R&D support for the other BBI business units as well as contract research services for third parties, and (4) BBI Source Scientific, an ISO 9001 certified manufacturer of laboratory and diagnostic instrumentation. In addition, BBI is pursuing a research and development program in Pressure Cycling Technology (PCT) through its subsidiary BBI BioSeq, with the goal of introducing new solutions for a number of important healthcare issues, including: inactivation of pathogens in human plasma, extraction of nucleic acids, food safety, and genomics. BBI also maintains a passive investment in Panacos Pharmaceuticals, a privately held antiviral drug and vaccine development company recently spun off from BBI, whose goal is to introduce new solutions for the detection and treatment of infectious diseases. BBI`s web address is www.bbii.com.

FORWARD LOOKING STATEMENTS
Specialty Laboratories, Inc.

This release may contain forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the results predicted and reported results should not be considered an indication of future performance. Important factors which could cause actual results to differ materially from those expressed or implied in the forward-looking statements are detailed under "Risk Factors" and elsewhere in filings with the Securities and Exchange Commission made from time to time by Specialty, including its Registration Statement on Form S-1 declared effective on December 7, 2000 (Registration No. 333-45588). Other factors that could cause our actual results to differ materially from those expressed or implied in the forward- looking statements are the risks that our business will not be integrated successfully with BBI, costs related to the proposed acquisition may exceed those that are expected, general economic conditions or conditions in BBI`s markets may change, and Specialty may be subject to increased or unexpected competition or fluctuations in demand from BBI`s customers. Specialty undertakes no obligation to release publicly any revisions to any forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Boston Biomedica, Inc.

Statements contained in this news release that state the intentions, hopes, beliefs, expectations or predictions of the future of Boston Biomedica are "forward-looking" statements. It is important to note that Boston Biomedica`s actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the failure of BBI Clinical Laboratories, Boston Biomedica or Specialty to successfully transition the operations of BBI Clinical Laboratories to Specialty Laboratories in a timely manner, if at all. In addition, there can be no assurance that the proceeds from the sale of assets will be adequate to fund Boston Biomedica`s foreseeable needs. Additional information concerning other factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in Boston Biomedica`s SEC filings, including but not limited to Boston Biomedica`s Registration Statements on Form S-3 (Reg. No. 333-46426 and Reg. No. 333-94379), Annual Report on Form 10-K for the year ended December 31, 1999 and Quarterly Reports on Form 10-Q for the periods ended March 31, June 30, and September 30, 2000. Copies of these documents may be obtained by contacting Boston Biomedica or the SEC. Visit us at our website http://www.bbii.com

Please email us at [e-mail] if you prefer to receive future announcements electronically


/CONTACT: Richard T. Schumacher, CEO & Chairman or Kevin W. Quinlan, President & COO or William R. Prather, M.D., Sr. VP Finance & Business Dvlp. of Boston Biomedica, Inc., 508-580-1900/

[zupf]

Vielen dank für deine mühe Spiewi !